Clinical Trial

The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Evaluation of the efficacy and safety of immunoadsorption or plasma exchange combined with rituximab and high-dose IVIG to reduce high titres of anti-HLA antibodies in patients prior to allogeneic haematopoietic stem cell transplantation
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-09.
Status change: Not Yet Recruiting → Recruiting 2024-12-16
Trial Details
NCT Number NCT06362967
Lead Sponsor Anhui Provincial Hospital
Conditions High Titers of Anti-HLA Antibody (MFI ≥5000)
Enrollment 30 participants
Start Date 2024-05-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-18